# Extension Study of PRX-102 for up to 60 Months

> **NCT01981720** · PHASE1,PHASE2 · COMPLETED · sponsor: **Protalix** · enrollment: 15 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** PRX-102 (pegunigalsidase alfa)

## Key facts

- **NCT ID:** NCT01981720
- **Lead sponsor:** Protalix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-16
- **Primary completion:** 2020-08-26
- **Final completion:** 2021-11-09
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01981720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01981720, "Extension Study of PRX-102 for up to 60 Months". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01981720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*